Oxford Cannabinoid Technologies nearly ready for new phase 1 trial | News Direct

Oxford Cannabinoid Technologies nearly ready for new phase 1 trial

Oxford Cannabinoid Technologies Holdings PLC
Digital Asset Direct by Oxford Cannabinoid Technologies Holdings PLC
Download PDF Download multimedia

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | November 15, 2022 10:22 AM Eastern Standard Time

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief scientific officer Dr Valentino Parravicini speaks to Proactive ahead of the Q1 2023 start of a new phase 1 trial for its lead compound, OCT461201. The study will target pain relief in those suffering from chemotherapy-induced peripheral neuropathy (CIPN) and irritable bowel syndrome (IBS).

 

Contact Details

 

Proactive

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2025 News Direct Corp. All rights reserved. News Direct is a registered trademark.